Jolltrin Capsule contains Trientine Hydrochloride 250 mg, a chelating agent primarily indicated for the treatment of Wilson’s disease, a genetic disorder characterized by excessive accumulation of copper in the body. Trientine acts by binding free copper ions, facilitating their excretion through urine, thereby reducing copper toxicity and preventing organ damage. This medication is typically prescribed for patients who are intolerant to penicillamine or as a second-line therapy. Jolltrin Capsule should be administered orally, with dosage individualized based on the patient’s clinical response and copper levels. Regular monitoring of serum copper, ceruloplasmin, and liver function tests is essential to assess therapeutic efficacy and detect potential adverse effects. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal discomfort, as well as hypersensitivity reactions. Rarely, hematological abnormalities or neurological worsening may occur, necessitating close clinical observation. Jolltrin Capsule is contraindicated in patients with known hypersensitivity to Trientine or its components. Caution is advised in patients with renal impairment. Adequate hydration should be maintained to prevent crystalluria. This medication should be used under strict medical supervision to ensure optimal management of copper levels and to minimize the risk of toxicity or treatment failure.